A research study to evaluate the effects of single doses of NNC0614-0001 in healthy adult volunteers, and participants with hereditary haemochromatosis type 1.
This research study is looking at a new medicine called NNC0614-0001. It's an early-stage study, meaning it's the first time this medicine is being given to people. The main goal is to understand how a single dose works in the body. Researchers will test it in two groups: healthy adults and people who have hereditary haemochromatosis type 1. Hereditary haemochromatosis is a genetic condition where the body absorbs too much iron, which can cause health problems over time. By testing it in both groups, scientists hope to learn if the medicine is safe and how it might help people with this condition. This is an important step in developing potential new treatments.
At a glance
What is this study about?
This study is a very early stage of research, often called a 'Phase 1' study. This means it's the first time the new medicine, NNC0614-0001, is being given to people. The main aim is to carefully check if the medicine is safe and how the body handles it after a single dose. Think of it like taking a new car for its first test drive – you want to make sure it's safe to drive and understand how it performs.
The study is looking for two groups of volunteers: healthy adults and people who have a condition called hereditary haemochromatosis type 1. Hereditary haemochromatosis is a common inherited condition where the body takes in too much iron from food. Over many years, this iron can build up in organs like the liver, heart, and pancreas, potentially causing damage.
By including both healthy people and those with hereditary haemochromatosis, researchers hope to see if the new medicine behaves differently in people with the condition. This information is crucial for understanding if NNC0614-0001 could eventually become a helpful treatment for people living with hereditary haemochromatosis in the future.
Key takeaways
- Tests a brand-new medicine for the first time in humans.
- Aims to check safety and how the medicine works after one dose.
- Includes both healthy volunteers and people with hereditary haemochromatosis type 1.
- Could help develop new treatments for this iron overload condition.
- Participation involves screening, a single dose, and follow-up visits.
Who may be eligible?
To join this study, you need to be an adult, aged 18 or older. Both men and women are welcome to take part. The study is looking for two types of people: healthy volunteers and people who have been diagnosed with hereditary haemochromatosis type 1.
The research team will carry out some checks to make sure the study is a good fit for you. This is important to keep you safe and ensure the study results are reliable. For example, they'll check your general health, and for those with hereditary haemochromatosis, they'll confirm your diagnosis. If you're generally healthy and interested in contributing to medical research, or if you have hereditary haemochromatosis type 1 and want to learn more, you might be eligible.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally healthy, or have you been diagnosed with hereditary haemochromatosis type 1?
- Are you comfortable potentially staying at a clinic for observation?
- Are you able to attend follow-up appointments?
- Are you willing to undergo medical checks and blood tests?
What does participation involve?
If you decide to take part, you'll first have a screening visit to check if you meet all the study requirements. This might involve a medical examination, blood tests, and reviewing your health history. If you're eligible, you will receive a single dose of the study medicine. This will usually happen during a stay at the research clinic, where you'll be carefully monitored by doctors and nurses. You will then have follow-up visits, which could involve more blood tests and check-ups, to see how your body reacted to the medicine. The total duration of your participation will depend on the follow-up schedule, but it will be explained in detail before you agree to join.
Potential risks and benefits
Locations (1)
- —UnverifiedAustria
Common questions
What is hereditary haemochromatosis type 1?
It's an inherited condition where your body takes in too much iron from your food. This extra iron can build up and potentially harm organs over time.
What is NNC0614-0001?
It's a new medicine being tested for the first time in people to see how it works and if it's safe. We don't know much about it yet.
Why is this study important?
It's a very early, but important, step in finding new and better ways to treat hereditary haemochromatosis.
Will I get paid for taking part?
Some studies offer payment for your time and travel, but this varies. The study team will tell you about any compensation during your initial discussion.
Will this medicine cure my haemochromatosis?
It's far too early to say. This study is only checking safety and how a single dose works. It's not designed to cure the condition at this stage.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.